Hunan Fangsheng Pharmaceutical Co Ltd
SSE:603998
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (24.1), the stock would be worth ¥16.6 (60% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.1 | ¥10.4 |
0%
|
| 3-Year Average | 24.1 | ¥16.6 |
+60%
|
| 5-Year Average | 17.8 | ¥12.29 |
+18%
|
| Industry Average | 25 | ¥17.25 |
+66%
|
| Country Average | 18.3 | ¥12.59 |
+21%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Hunan Fangsheng Pharmaceutical Co Ltd
SSE:603998
|
4.6B CNY | 15.1 | 15.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 49.7 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 22.3 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 19.7 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 14.3 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 16.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 13.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.3 | 16.8 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Hunan Fangsheng Pharmaceutical Co Ltd
Glance View
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in the manufacture, distribution, research and development of pharmaceutical products. The company is headquartered in Changsha, Hunan and currently employs 2,808 full-time employees. The company went IPO on 2014-12-05. The firm's main products include Xuesaitong Dispersible Tablets, Xuesaitong Tablets, Tenghuang Jiangu Tablets, Dieda Huoxue Capsules, Lysine Dimension B12 Granules, Cefixoxime Tablets and Jinying Capsules. The firm distributes its products primarily in domestic market.
